Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Generic

Thumbnail
September 26, 2019

How Labour’s UK generic drugs plan could have been better

Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.

Thumbnail
May 14, 2019

Price fixing case caps a terrible week for generics

Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector. 

Article image
Vantage logo
September 07, 2018

Civica Rx goes where generics companies fear to tread

A non-profit partnership of 500 hospitals wants to deliver its first generic drugs in 2019, lowering prices and stabilising supplies.

Vantage logo
May 15, 2018

Pfenex readies to swim upstream with Forteo copycat

Vantage logo
May 03, 2018

Biosimilar knockbacks expose increasing big pharma focus

Vantage logo
April 17, 2018

Private equity cleans up Sanofi’s failed generics foray

Vantage logo
February 20, 2018

Interview – Rani’s pill injector promises much, but is still preclinical

Vantage logo
January 24, 2018

Novartis investors put faith in new chief

Vantage logo
December 14, 2017

Teva investors applaud and staff revolt, as Schultz swings the axe

Article image
Vantage logo
October 04, 2017

A determined FDA takes down Teva’s blockbuster

Earlier-than-expected US approval for Mylan's generic version of Teva's Copaxone is a blow to the struggling Israeli firm.

Vantage logo
September 28, 2017

Abbvie sets the date for cash cow slaughter

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.